Podcasts about parp inhibition

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications

Featuring perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics: Introduction (0:00) Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22) Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson (38:06) CME information and select publications

CME credits: 1.00 Valid until: 27-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-and-clinical-outcomes-with-parp-inhibitors-for-advanced-ovarian-cancer-cytogenetic-testing-and-parp-inhibition-for-maintenance-treatment/15664/ The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life. In this educational activity, expert faculty will review the role of genetic testing in identifying patients likely to benefit …=

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.25.532215v1?rss=1 Authors: Zamalloa, L. G., Pruitt, M. M., Hermance, N. M., Gali, H., Flynn, R. L., Manning, A. L. Abstract: The retinoblastoma tumor suppressor protein (RB) interacts physically and functionally with a number of epigenetic modifying enzymes to control transcriptional regulation, respond to replication stress, promote DNA damage response and repair pathways, and regulate genome stability. To better understand how disruption of RB function impacts epigenetic regulation of genome stability and determine whether such changes may represent exploitable weaknesses of RB-deficient cancer cells, we performed an imaging-based screen to identify epigenetic inhibitors that promote DNA damage and compromise viability of RB-deficient cells. We found that loss of RB alone leads to high levels of replication-dependent poly-ADP ribosylation (PARylation) and that preventing PARylation through inhibition of PARP enzymes enables RB-deficient cells to progress to mitosis with unresolved replication stress and under-replicated DNA. These defects contribute to high levels of DNA damage, decreased proliferation, and compromised cell viability. We demonstrate this sensitivity is conserved across a panel of inhibitors that target both PARP1 and PARP2 and can be suppressed by re-expression of the RB protein. Together, these data indicate that inhibitors of PARP1 and PARP2 may be clinically relevant for RB-deficient cancers. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Featuring an interview with Drs Gottfried Konecny and Chirag Patel, including the following topics: •      Tumor Treating Fields with Chirag B Patel, MD, PhD  o   Introduction (0:00) o   Mechanism of action of tumor treating fields (5:53) o   Tumor treating fields for glioblastoma multiforme (25:08) o   Tumor treating fields for other tumor types (28:50) o   Case presentations (34:10) •      Updates on PARP Inhibitors in 2023 with Gottfried E Konecny, MD  o   PARP inhibitors as up-front maintenance therapy for ovarian cancer (37:15) o   PARP inhibitors for recurrent ovarian cancer (44:34) CME information and select publications

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06) Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22) Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02) CME information and select publications

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics: Keys to evaluating genetics in patients with ovarian cancer (0:00) Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35) Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45) Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37) CME information and select publications

Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarianPARP22).

Featuring a discussion of the current role of PARP inhibitors in the care of patients with ovarian cancer with Dr Thomas Herzog, moderated by Dr Neil Love.

In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes? Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes? Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

An inch wide and a mile deep—that's the sort of expertise CSO of Artios Pharma, Dr. Graeme Smith, brings his benchtop. Since his time at Cambridge, Smith has been laser focused on DDR mechanisms, first elucidating, and then translating those observations to create the PARP inhibitor drug, Lynparza. Developed at Kudos Pharma, and later, AstraZeneca, hear Smith recall his “aha” moment for this first-in-class blockbuster drug, as well as his descriptions of his two new DDR-targeting, clinical stage assets developed at Artios that leverage his knowledge of novel DDR pathways—including those that will overcome resistance to PARP inhibition.

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono CME information and select publications

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad CME information and select publications

Featuring a discussion on PARP inhibition in the management of prostate cancer with Prof Johann de Bono and Dr Fred Saad, moderated by Dr Neil Love.

Pete Nelson describes mechanism of action and current clinical application in prostate cancer

Featuring a discussion on recent advances in the treatment of pancreatic cancer with PARP with Dr Michael Pishvaian, moderated by Dr Neil Love.

Featuring a discussion on recent advances in the treatment of pancreatic cancer with PARP with Dr Michael Pishvaian, moderated by Dr Neil Love.

Featuring a discussion on recent advances in the treatment of pancreatic cancer with PARP with Dr Michael Pishvaian, moderated by Dr Neil Love.

Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPancreasPARP21).

Featuring an interview with Dr Michael Pishvaian, including the following topics: Case: A woman in her late 50s with metastatic pancreatic cancer with diffuse liver metastases (0:00) Case: A woman in her mid-60s with resectable pancreatic cancer who underwent Whipple surgery (28:52) Case: A woman in her early 50s with locally advanced unresectable pancreatic adenocarcinoma (30:51) CME information and select publications

Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarian21).

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Neeraj Agarwal and Daniel Petrylak, including the following topics: Introduction Case: A woman in her early 50s with metastatic renal cell carcinoma with rhabdoid features — Dr Kumar Comparing First-Line Treatment Options for Metastatic Renal Cell Carcinoma Chalk Talk — Dr Petrylak Second-Line Treatment of Metastatic Renal Cell Carcinoma After Progression on Checkpoint Inhibitor-Based Therapy Chalk Talk — Dr Agarwal Case: A healthy man in his late 80s with locally recurrent castration-resistant prostate cancer (CRPC) — Dr Guancial Case: A man in his mid-80s with metastatic CRPC and a somatic BRCA2 mutation — Dr Zafar 177Lu-PSMA-617 in Metastatic CRPC Chalk Talk — Dr Agarwal Case: A man in his early 60s with metastatic CRPC and an ATM mutation — Dr Shameem Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Case: A woman in her late 70s with non-muscle-invasive urothelial bladder cancer — Dr Gandhi Case: A man in his late 60s with localized urothelial bladder carcinoma (UBC) — Dr Choksi Case: A woman in her early 70s with high-TMB muscle-invasive UBC and high-PD-L1 expression — Dr Guancial Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Sequencing Enfortumab Vedotin and Other Targeted Therapies for Metastatic UBC Chalk Talk — Dr Agarwal CME information and select publications

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics: Introduction (0:00) Case: A woman in her late 60s with recurrent serous papillary adenocarcinoma of the fallopian tube with a germline BRCA1 mutation — Yanjun Ma, MD (5:24) Case: A woman in her mid-60s with Stage IIIC fallopian tube carcinoma with no deleterious mutations — Lyndsay J Willmott, MD (9:11) Case: A woman in her late 70s with ovarian cancer (OC) and a germline BRCA2 mutation — Shachar Peles, MD (14:22) Case: A woman in her mid-40s with Stage IIIC serous OC and a germline BRCA1 mutation — Dr Wilmott (17:06) PARP inhibitor maintenance therapy (23:32) Case: A woman in her late 60s with Stage IV OC and a germline BRCA1 mutation — Laurie Matt-Amaral, MD, MPH (39:43) Case: A woman in her late 70s with Stage IIIC OC with a germline BRCA mutation who develops anemia on olaparib — Sulfi Ibrahim, MD (43:55) Niraparib-associated thrombocytopenia and surgical procedures — Heidi E Godoy, DO (47:14) Case: A woman in her mid-70s with recurrent OC and a germline and somatic BRCA2 mutation — Dana M Chase, MD (50:42) Novel strategies with PARP inhibitors in OC (53:38) CME information and select publications

Featuring slide presentations and related discussion from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics: Genetic Testing in Ovarian Cancer: Integration of PARP Inhibitor Maintenance into the Management of Newly Diagnosed BRCA Mutation-Positive Ovarian Cancer — Susana Banerjee, MBBS, MA, PhD (0:00) Clinical Utility of PARP Inhibitor Maintenance in Patients with BRCA Wild-Type Advanced Ovarian Cancer — Richard T Penson, MD, MRCP (42:11) PARP Inhibitors in Combination with Immunotherapeutic and Chemotherapeutic Agents in the Management of Advanced Ovarian Cancer — Shannon N Westin, MD, MPH (1:15:14) CME information and select publications

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon N Westin, moderated by Neil Love, MD.

Featuring perspectives from Dr Joyce O'Shaughnessy on following topics: Introduction (0:00) Case Presentations from Alan B Astrow, MD on Chemotherapy for Triple-Negative Breast Cancer (TNBC) A woman in her late 80s with triple-negative lobular carcinoma (1:54) A woman in her mid-60s with triple-negative, node-positive breast cancer (6:30) A woman in her early 30s with triple-negative, node-negative infiltrating ductal carcinoma (IDC) (14:39) San Antonio Breast Cancer Symposium (SABCS®) Review — Immunotherapy for Advanced TNBC (20:25) Case Presentations from Dr Astrow and SABCS Review of Data on Immunotherapy Combinations and PARP Inhibition for TNBC A woman in her early 40s with metastatic TNBC (31:08) A woman in her early 60s with a germline BRCA1 mutation and locally advanced breast cancer (36:14) Case Presentations from Dr Astrow on Triple-Negative Small Cell Carcinoma of the Breast and Triple-Negative IDC; Sacituzumab Govitecan for Patients with TNBC A woman in her mid-40s with triple-negative small cell carcinoma of the breast (48:11) A woman in her late 30s with triple-negative IDC (51:44) CME information and select publications

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaNeal D. Shore, MD, FACSDirectorCarolina Urologic Research CenterAtlantic Urology ClinicsMyrtle Beach, South CarolinaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/2P31ZqF

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid discusses the latest clinical data on and optimal integration of PARP inhibitors in ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayFrontLineCLL21).

Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySGOPARP21).

Featuring a discussion on the evolving role of PARP inhibition in the management of ovarian cancer with Dr Shannon N Westin, moderated by Dr Neil Love.

Featuring an interview with Dr Shannon N Westin on the following topics: Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00) Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46) Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51) Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56) Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15) Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03) Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32) Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19) Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09) Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14) Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53) CME information and select publications

Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discusses the role of PARP inhibition in the management of ovarian cancer.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayASCOOvarian20)

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

Dr Maha Hussain discusses the role of PARP inhibitors in the treatment of prostate cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).

Dr Ursula Matulonis discusses the role of PARP inhibitors in the treatment of ovarian cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).

Featuring a discussion on recent data with PARP inhibitors in the treatment of breast, ovarian, pancreatic and prostate cancer with Drs Hope Rugo, Ursula Matulonis, Philip A Philip and Maha Hussain, moderated by Neil Love, MD.

Dr Hope Rugo discusses the role of PARP inhibitors in the treatment of breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).

Featuring a discussion on recent advances in the use of PARP inhibitors in pancreatic cancer with Dr Kim Reiss Binder, moderated by Neil Love, MD.

Featuring a discussion on recent advances in the use of PARP inhibitors in pancreatic cancer with Dr Kim Reiss Binder, moderated by Neil Love, MD.

A special audio program developed from the tenth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Emmanuel S Antonarakis, Ms Gretchen Santos Fulgencio, Dr Kathleen Moore, Dr Joyce O'Shaughnessy, Dr Michael J Pishvaian and Ms Deborah Wright.

A special audio program developed from the tenth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Emmanuel S Antonarakis, Ms Gretchen Santos Fulgencio, Dr Kathleen Moore, Dr Joyce O'Shaughnessy, Dr Michael J Pishvaian and Ms Deborah Wright.

PARP Inhibition in Four Common Cancers: Biology, Clinical Research Database and Therapeutic Strategy. Featuring Emmanuel S Antonarakis, MD, Kathleen Moore, MD, Michael J Pishvaian, MD, PhD and Melinda Telli, MD. Moderated by Neil Love, MD. Produced by Research To Practice.

PARP Inhibition in Four Common Cancers: Biology, Clinical Research Database and Therapeutic Strategy. Featuring Emmanuel S Antonarakis, MD, Kathleen Moore, MD, Michael J Pishvaian, MD, PhD and Melinda Telli, MD. Moderated by Neil Love, MD. Produced by Research To Practice.